| Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm … JW Day, RS Finkel, CA Chiriboga, AM Connolly, TO Crawford, BT Darras, ... The Lancet Neurology 20 (4), 284-293, 2021 | 304 | 2021 |
| A 3‐week, randomized, placebo‐controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states RS McIntyre, M Cohen, J Zhao, L Alphs, TA Macek, J Panagides Bipolar disorders 11 (7), 673-686, 2009 | 249 | 2009 |
| Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial RS McIntyre, M Cohen, J Zhao, L Alphs, TA Macek, J Panagides Journal of affective disorders 122 (1-2), 27-38, 2010 | 211 | 2010 |
| Differential involvement of group II and group III mGluRs as autoreceptors at lateral and medial perforant path synapses TA Macek, DG Winder, RW Gereau 4th, CO Ladd, PJ Conn Journal of neurophysiology 76 (6), 3798-3806, 1996 | 209 | 1996 |
| Sleep, Sleep Disorders, and Mild Traumatic Brain Injury. What We Know and What We Need to Know: Findings from a National Working Group EM Wickwire, SG Williams, T Roth, VF Capaldi, M Jaffe, M Moline, ... Neurotherapeutics 13 (2), 403-417, 2016 | 155 | 2016 |
| Protein kinase C and A3 adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins TA Macek, H Schaffhauser, PJ Conn Journal of Neuroscience 18 (16), 6138-6146, 1998 | 151 | 1998 |
| Asenapine versus olanzapine in acute mania: a double‐blind extension study RS McIntyre, M Cohen, J Zhao, L Alphs, TA Macek, J Panagides Bipolar disorders 11 (8), 815-826, 2009 | 147 | 2009 |
| Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial KA Strauss, MA Farrar, F Muntoni, K Saito, JR Mendell, L Servais, ... Nature medicine 28 (7), 1381-1389, 2022 | 141 | 2022 |
| Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study RS McIntyre, M Cohen, J Zhao, L Alphs, TA Macek, J Panagides Journal of affective disorders 126 (3), 358-365, 2010 | 140 | 2010 |
| Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study RS McIntyre, M Cohen, J Zhao, L Alphs, TA Macek, J Panagides Journal of affective disorders 126 (3), 358-365, 2010 | 140 | 2010 |
| Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial KA Strauss, MA Farrar, F Muntoni, K Saito, JR Mendell, L Servais, ... Nature medicine 28 (7), 1390-1397, 2022 | 115 | 2022 |
| A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine SD Undevia, HL Kindler, L Janisch, SC Olson, RL Schilsky, NJ Vogelzang, ... Annals of oncology 15 (11), 1705-1711, 2004 | 84 | 2004 |
| cAMP-dependent protein kinase inhibits mGluR2 coupling to G-proteins by direct receptor phosphorylation H Schaffhauser, Z Cai, F Hubalek, TA Macek, J Pohl, TJ Murphy, PJ Conn Journal of Neuroscience 20 (15), 5663-5670, 2000 | 79 | 2000 |
| Dissociation of protein kinase-mediated regulation of metabotropic glutamate receptor 7 (mGluR7) interactions with calmodulin and regulation of mGluR7 function SD Sorensen, TA Macek, Z Cai, JA Saugstad, PJ Conn Molecular pharmacology 61 (6), 1303-1312, 2002 | 46 | 2002 |
| A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia TA Macek, M McCue, X Dong, E Hanson, P Goldsmith, J Affinito, ... Schizophrenia research 204, 289-294, 2019 | 36 | 2019 |
| A human [11C] T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor A Takano, P Stenkrona, V Stepanov, N Amini, S Martinsson, M Tsai, ... Neuroimage 141, 10-17, 2016 | 28 | 2016 |
| Activation of PKC disrupts presynaptic inhibition by group II and group III metabotropic glutamate receptors and uncouples the receptor from GTP‐binding proteins TA Macek, H Schaffhauser, PJ Conn Annals of the New York Academy of Sciences 868 (1), 554-557, 1999 | 26 | 1999 |
| Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: a phase 3, randomized controlled trial AR Mahableshwarkar, JR Calabrese, TA Macek, K Budur, A Adefuye, ... Journal of affective disorders 221, 275-282, 2017 | 23 | 2017 |
| Onasemnogene Abeparvovec gene therapy in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update in children with 2 copies of SMN2 (4190) K Strauss, F Muntoni, M Farrar, K Saito, J Mendell, L Servais, H McMillan, ... Neurology 96 (15 Supplement), 2021 | 21 | 2021 |
| Onasemnogene abeparvovec-xioi gene-replacement therapy for spinal muscular atrophy type 1 (SMA1): phase 3 US study (STR1VE) update (1828) JW Day, CA Chiriboga, TO Crawford, BT Darras, RS Finkel, AM Connolly, ... Neurology 94 (15 Supplement), 2020 | 21 | 2020 |
